Information Provided By: 
Fly News Breaks for March 3, 2020
PTCT
Mar 3, 2020 | 07:05 EDT
Cantor Fitzgerald analyst Alethia Young raised the firm's price target on PTC Therapeutics to $86 from $81 and reiterates an Overweight rating on the shares. The analyst remains positive on PTC shares heading into the FIREFISH Type 1 readout in April. Young also wonders if risdiplam might be approved before its approval data on May 24. The stock reflects a lot of credit for risdiplam, "but we still really like PTC over the next 12 months due to various catalysts on the horizon," Young tells investors in a research note.
News For PTCT From the Last 2 Days
There are no results for your query PTCT
